Montag & Associates’s AstraZeneca AZN Stock Holding History

Montag & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-371	Closed	-$56.9K	–	974
2025 Q3	$56.9K	Buy	371 +326	+724%	+$49.3K	﹤0.01%	571
2025 Q2	$6.29K	Buy	+45	New	+$6.31K	﹤0.01%	784
2025 Q1	–	Sell	-5	Closed	-$656	–	1000
2024 Q4	$656	Hold	5	–	–	﹤0.01%	976
2024 Q3	$780	Buy	+5	New	+$807	﹤0.01%	998
2018 Q2	–	Sell	-4,700	Closed	-$329K	–	279
2018 Q1	$329K	Hold	4,700	–	–	0.03%	236
2017 Q4	$326K	Hold	4,700	–	–	0.03%	238
2017 Q3	$318K	Hold	4,700	–	–	0.03%	213
2017 Q2	$320K	Hold	4,700	–	–	0.04%	208
2017 Q1	$293K	Hold	4,700	–	–	0.03%	211
2016 Q4	$257K	Hold	4,700	–	–	0.03%	218
2016 Q3	$309K	Hold	4,700	–	–	0.04%	210
2016 Q2	$284K	Hold	4,700	–	–	0.04%	211
2016 Q1	$265K	Hold	4,700	–	–	0.04%	214
2015 Q4	$319K	Hold	4,700	–	–	0.05%	192
2015 Q3	$299K	Hold	4,700	–	–	0.05%	196
2015 Q2	$299K	Hold	4,700	–	–	0.04%	209
2015 Q1	$322K	Hold	4,700	–	–	0.05%	210
2014 Q4	$331K	Buy	+4,700	New	+$337K	0.05%	203

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Montag & Associates's AZN Position: Q4 2025 in Review

Montag & Associates sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 371 shares — an estimated $56.9K sold.

Montag & Associates first reported a position in AZN in Q4 2014 and held it in 18 quarters. The position peaked at $331K in Q4 2014. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Montag & Associates reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Montag & Associates sold 371 AstraZeneca shares in Q4 2025, an estimated $56.9K.
Montag & Associates first reported a position in AstraZeneca in Q4 2014 and held it in 18 quarters.
Montag & Associates's AstraZeneca position peaked at $331K in Q4 2014.
1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.